What's Happening?
The PEACE-3 trial, an international Phase III study, has demonstrated that the combination of Bayer's XOFIGO (radium-223 dichloride) and enzalutamide significantly improves overall survival in patients with metastatic castration-resistant prostate cancer
(mCRPC) with bone metastases. The trial showed a 24% reduction in the risk of death compared to enzalutamide alone, with median overall survival extending to 38.2 months versus 32.6 months. The trial, conducted by the European Organization for Research and Treatment of Cancer, also highlighted the safety profile of the combination, noting that 69% of patients experienced Grade 3 or higher treatment-emergent adverse events. The results will be presented at the ASCO GU 2026 symposium.
Why It's Important?
This development is significant as it offers a new potential treatment strategy for mCRPC patients, a group that faces a poor prognosis and high risk of disease progression. The combination therapy could become a new standard of care, improving survival rates and quality of life for patients. The trial underscores the importance of international collaboration in cancer research, providing valuable data that could influence clinical decision-making and treatment guidelines. Bayer's commitment to prostate cancer care is reinforced, potentially expanding their market presence and offering new hope to patients with limited treatment options.
What's Next?
The final results of the PEACE-3 trial will be presented at the ASCO GU 2026 symposium, which could lead to further discussions on the integration of this combination therapy into clinical practice. Regulatory bodies may consider these findings for potential approval of the combination therapy, expanding its use beyond current indications. The trial's outcomes may also prompt additional research into combination therapies for other cancer types, potentially broadening the scope of treatment options available to patients.
